e8vk
 
 
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of Earliest Event Reported): May 20, 2010
Cytokinetics, Incorporated
(Exact name of registrant as specified in its charter)
         
Delaware   000-50633   94-3291317
         
(State or other jurisdiction
of incorporation)
  (Commission
File Number)
  (I.R.S. Employer
Identification No.)
     
280 East Grand Avenue, South San Francisco,
California
  94080
     
(Address of principal executive offices)   (Zip Code)
Registrant’s telephone number, including area code:(650) 624 — 3000
Not Applicable
Former name or former address, if changed since last report
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
o Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
o Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
o Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
o Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
 
 

 


 

ITEM 5.07. Submission of Matters to a Vote of Security Holders.
     On May 20, 2010, Cytokinetics, Inc. (the “Company”) held its Annual Meeting of Stockholders in South San Francisco, California. Of the 62,464,802 shares of the Company’s common stock entitled to vote at the meeting, 53,790,766 shares of common stock, or 86.11%, of the total eligible votes to be cast, were represented at the meeting in person or by proxy, constituting a quorum. The final results of voting for each matter submitted to a vote of stockholders at the meeting were as follows:
Proposal 1: Election of Directors
     The stockholders elected Stephen Dow, John T. Henderson and Michael Schmertzler as Class III directors, each to serve for a three-year term and until their successors are duly elected and qualified. The voting for each director was as follows:
                         
Name   For     Withheld     Broker Non-Vote  
Stephen Dow
    44,204,604       303,937       9,282,225  
John T. Henderson
    44,165,556       342,985       9,282,225  
Michael Schmertzler
    42,878,496       1,630,045       9,282,225  
Proposal 2: Ratification of Independent Registered Public Accounting Firm
     The stockholders ratified the selection by the Audit Committee of the Board of Directors of PricewaterhouseCoopers LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2010. The votes were as follows:
                         
For   Against   Abstain   Broker Non-Vote
53,575,238
    143,987       71,541       0  
 
Proposal 3: Approval of an Amendment to the Company’s 2004 Equity Incentive Plan
 
     The stockholders approved an amendment to the 2004 Equity Incentive Plan, as amended, to increase the number of authorized shares reserved for issuance thereunder by 2,300,000 shares. The votes were as follows:
 
For   Against   Abstain   Broker Non-Vote
37,691,035
    4,498,757       2,318,749       9,282,225  

 


 

SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
         
  Cytokinetics, Incorporated
 
 
May 24, 2010   By:   /s/ Sharon A. Barbari    
    Name:   Sharon A. Barbari   
    Title:   Executive Vice President, Finance and
Chief Financial Officer